A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

NCT07462468 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer (PROC)

Interventions

DRUG: WSK-IM02
DRUG: WSK-IM02

Sponsor

WestVac Biopharma Co., Ltd.